Gavi, a world vaccine alliance, has made a $5 million deal with Merck regarding vaccine supply for future outbreaks. Merck has to provide 300,000 vaccines as a preparation to protect people from the next Ebola crisis.
The president of Russia, Vladimir Putin, announced that his country had found two vaccines to cure Ebola. However, the announcement has drawn some skepticism among experts who have previously developed other vaccines for Ebola.
At least 40 major U.S. companies have substantial exposure to Venezuela’s deepening economic crisis, and could collectively be forced to take billions of dollars of write downs, a Reuters analysis shows.
Merck & Co Inc (MRK.N) said it would buy Cubist Pharmaceuticals Inc (CBST.O) for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.
Merck KGaA (MRCG.DE) aims to keep hold of its consumer healthcare unit, it said on Friday, pledging to develop a business that is expected to generate 2014 sales of $1 billion for the German drugs and chemicals company.
Merck & Co Inc (MRK.N) on Monday said it would buy worldwide commercial rights to NewLink Genetics Corp's (NLNK.O) experimental vaccine against the Ebola virus.
Ablynx, a Belgian biotechnology firm, has agreed to a €20 million deal with Merck to develop immunotherapies that can bolster the human body's potential to combat cancer cells, the Financial Times reported.
UK asset manager Threadneedle Investments has increased its stake in AZ Electronic Materials to above 11% in a move that could block the GBP1.56 billion takeover bid from German drugmaker Merck.
German healthcare group Merc is looking for acquisitions and collaborations with start-ups to grow its drugs business in the United States, a senior Merck official said.
Illinois-based niche pharmaceutical firm Akorn Inc acquired the US rights to three branded ophthalmic products from New Jersey-based international pharmaceutical company Merck for USD52.8 million.
Merck and Pfizer announce deal for the inclusion of ertugliflozin into current diabetes drug portfolios of the companies.